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Worms have co-evolved with humans over millions of years. To survive, they manipulate host systems by
modulating immune responses so that they cause (in the majority of hosts) relatively subtle harm.
Anthelminthic treatment has been promoted as a measure for averting worm speciﬁc pathology and to miti-
gate subtle morbidities which may include effects on anaemia, growth, cognitive function and economic
activity. With our changing environment marked by rapid population growth, urbanisation, better hygiene
practices and anthelminthic treatment, there has been a decline in worm infections and other infectious dis-
eases and a rise in non-communicable diseases such as allergy, diabetes and cardiovascular disease. This
review reﬂects upon our age-old interaction with worms, and the broader ramiﬁcations of life without worms
for vaccine responses and susceptibility to other infections, and for allergy-related and metabolic disease. We
touch upon the controversy around the beneﬁts of mass drug administration for the more-subtle morbidities
that have been associated with worm infections and then focus our attention on broader, additional aspects
of life without worms, which may be either beneﬁcial or detrimental.
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Introduction
Over a billion people are estimated to be infected with hel-
minths, most living in areas of poverty.1,2 Helminths have co-
existed with mammals for millions of years. Their lifecycles have
evolved to ensure their survival while minimising harm to the
mammalian host. Soil transmitted helminths (STH) such as hook-
worm, Ascaris lumbricoides, Trichuris trichiura and Strongyloides
stercoralis spend part of their lifecycle in soil and gain access to
their human host through skin penetration or ingestion. For the
ﬁlarial nematodes, an insect vector takes up microﬁlariae dur-
ing a blood meal and, after development in the insect, the
parasite is injected into the next host during another blood
meal. For water borne helminths such as Schistosoma, cer-
cariae shed by the snail intermediate host access the deﬁnitive
human host by skin penetration during contact with infested
water. After migratory and development stages, adult worms
lodge in body tissues such as the gut, blood vessels and lym-
phatics. In most cases, helminths do not replicate in the mam-
malian host.3
Helminths induce short and long term morbidity, and path-
ology in some body systems: gastrointestinal tract (malabsorp-
tion, diarrhoea, macro and micronutrient deﬁciencies, bleeding,
intestinal obstruction, rectal prolapse), liver (peri-portal ﬁbrosis,
cholangitis, cholangiocarcinoma, hepatocellular carcinoma),
cardiovascular system (anaemia), lymphatic system (lymphoe-
dema), central nervous system (blindness, epilepsy), genito-
urinary tract (haematuria, hydronephrosis, bladder cancer),
lungs (Loefﬂer’s syndrome).4 These effects depend on the type
and number of helminths in the host. Treatment is deserved to
avert these harmful effects.
Societies in developing countries are experiencing remarkable
population growth, urbanisation and lifestyle changes. With bet-
ter hygiene and ‘deworming’ interventions, helminth infections
are declining. Concurrently, there is a rise in non-communicable
diseases (NCDs) such as diabetes5 and cardiovascular diseases,6
contributing signiﬁcantly to global mortality and attributed
largely to changes in diet and lifestyle. Could the decline in hel-
minth infections be playing a role in this epidemiological trans-
ition? With helminth elimination the ultimate goal of mass drug
administration (MDA) programmes,7 it is of interest to reﬂect on
the prospect of a worm-free life. Do we clearly understand, are
we ready for, the consequences of life divorced from the part-
nership established over millions of years? In this narrative
review we discuss current evidence regarding the beneﬁts of
MDA, ways in which worms manipulate us, and the possible
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effects of helminth infection on responses to vaccines and unre-
lated infectious diseases, and on allergy and metabolic disease.
How much do we beneﬁt from MDA?
MDA entails administration of anthelminthic medicines without
reference to an individual’s infection status, or test of cure. The
World Health Assembly endorsed MDA for school children as a
schistosomiasis and STH control strategy for high transmission
settings8 and this has been widely adopted.
MDA policy is premised on anticipated beneﬁts for helminth-
speciﬁc pathology, maternal anaemia, birth weight, childhood
growth, anaemia, cognitive function, school performance and
long term economic returns. We do not question the beneﬁt of
MDA for controlling pathologies such as schistosome-induced
ﬁbrosis, hookworm-induced anaemia, elephantiasis and river
blindness. However, the impact of MDA on more subtle morbid-
ities associated with helminths has been difﬁcult to demonstrate.
Mass treatment for hookworm in the American south at the
turn of 20th century was associated with greater school enrol-
ment, attendance and literacy and long-term gain in income.9
Further, in 2004, Miguel and Kremmer published a highly inﬂu-
ential report showing an association between school-based
MDA and reduced school absenteeism among Kenyan chil-
dren.10 Ten years later, these children who were dewormed at
school had more years of school enrolment, more time in
employment and longer work hours each week.11 However,
recent reanalyses of the original data have highlighted the chal-
lenges of evaluating such interventions.12,13
A large cluster-randomised trial in India with one million pre-
school children showed little effect of regular deworming on
mortality in pre-school children.14 A Cochrane review15 con-
cluded that treating children known to have STH may improve
weight gain but evidence of beneﬁts on haemoglobin, school
attendance and cognitive function is limited; also that commu-
nity based treatment programmes had little or no effect on
these outcomes. Similarly, a systematic review found the evi-
dence insufﬁcient to link helminths to cognitive performance16
and a further meta-analysis concluded that mass deworming of
children had little or no effect on weight, height, cognition,
school attendance or mortality.17
WHO recommends anthelminthic treatment during preg-
nancy, hoping that it will reduce maternal anaemia, increase
birth weight and reduce mortality. The beneﬁts are not yet
clear.18 We, and others, have found limited overall effects19 of
anthelminthic use during pregnancy on maternal anaemia, and
none on birth weight, perinatal mortality or congenital abnor-
malities.20–23 Anthelminthic treatment during pregnancy did not
affect infectious disease incidence or response to immunisa-
tion.24,25 A Cochrane review notes that evidence is insufﬁcient
to recommend use of anthelminthic medication for pregnant
women in the ﬁrst trimester and administration of a single dose
anthelminthic was not associated with any impact on maternal
anaemia.26
There has been debate on the policy of MDA27 and system-
atic review methodology has been questioned in its application
to helminths.28,29 However, it brings to light the need for more
evidence to support MDA and to understand fully its beneﬁts.
How do worms manipulate us?
The age-old colonisation of mammals by helminths has been
successful mainly because of the latter’s shrewd manipulation
of host systems (Figure 1).
Helminths employ enzymes and other excretory/secretory
proteins to disrupt and alter host tissues, thus successfully
migrating, feeding, establishing niches and developing strategies
to exit the host to complete their life-cycles. For example,
Schistosoma cercariae contain proteases that aid in skin pene-
tration30 while the major excretory/secretory protein of Trichuris
trichiura induces pore formation to facilitate helminth entrench-
ment in the gut.31
Loss of mucosal and epithelial integrity as helminths take root
in the host is often accompanied by release of inﬂammatory
mediators, such as alarmins and damage associated molecular
patterns,32 normally detrimental to the helminth and its host.
However, helminth excretory/secretory products also work to off-
set this. For example, secreted products of Heligmosomoides
polygyrus block production of the alarmin IL-33, a key inducer of
Th2-type inﬂammation.33 Besides, to curb host morbidity from
helminth-inﬂicted tissue injury, helminth-induced mediators
spearhead tissue healing and remodelling.34
But perhaps the helminth’s most potent survival weapon is
the wide array of mechanisms developed to evade or regulate a
vigilant host immune system. At the helm are helminth-induced
Th2-type and regulatory immune responses. Helminth-induced
Th2 cytokines interleukin (IL)-4 and IL-13 promote alternative
activation of macrophages, resulting in production of large
amounts of immunomodulatory IL-10 and transforming growth
factor (TGF)-β,35 and T cell hypo-responsiveness involving regula-
tory T cells.36 Helminth-induced, IL-10-producing ‘regulatory B
cells’ have also been demonstrated.37 A notable consequence
of helminth-induced immunomodulation is the attenuation of
responses to ‘bystander’ antigens,38 widely implicated in the
helminth-associated modulation of immune responses to a
number of non-communicable and communicable diseases.
Helminth-allergy interactions are a good example of the
bystander effect. Although antigenic targets for allergen- and
helminth-speciﬁc immune responses are similar,39 helminth
infections seem to be protective against allergy-related condi-
tions in both humans and mice. Current evidence32,40 points to
an extensive array of immunomodulatory mechanisms under-
lying inverse helminth-allergy associations. They range from
induction of IL-10-producing regulatory T cells, regulatory B cells
and alternatively activated antigen presenting cells, promotion
of polyclonal IgE synthesis and immunoglobulin class switching
to IgG4, to suppression of release of alarmins (such as IL-33)
and inhibition of type 2 innate lymphoid cell activity.
Host metabolic responses may also be inﬂuenced by
helminth infections. For example, S. mansoni egg antigen-
treated obese mice have increased levels of white adipose
tissue Th2-type cells, modiﬁed macrophage activation and
reduced adipose tissue mass and improved insulin sensitiv-
ity.41 Non-obese diabetic mice infected with H. polygyrus and
Trichinella spiralis are protected against type-1 diabetes
through the Th2-associated reduction of inﬂammatory auto-
immune responses.42 There is also recent evidence in humans
and mice that helminths may protect against inﬂammatory
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bowel diseases through Th2-type immunity-mediated expansion
of a protective microbiota.43
Helminth-induced bystander response suppression is a
double-edged sword. We may beneﬁt from helminth-driven
regulation of non-communicable diseases, as elaborated above.
However, helminth excretory/secretory products and Th2 cyto-
kines have been shown to suppress anti-microbial functions of
innate immune cells (dendritic cells and macrophages), leading
to increased differentiation of regulatory T cells and Th2 cells
while impeding the development of protective Th1-type
responses and potentially compromising immunity to several
communicable diseases.
Worms and vaccines
Following recognition of the Th1/Th2 hypothesis,44 the contrast-
ing ability of mycobacterial and helminth antigens to elicit Th1
and Th2 responses, respectively, and mutual inhibition between
these opposing effects,45 it was proposed that helminth co-
infection might account for the poor efﬁcacy of vaccines such
as BCG in tropical settings and the high prevalence of TB and
HIV in Africa.46 As helminth prevalence declines, will vaccines
become more effective, and susceptibility to other infectious
diseases decrease?
Studies in animal models largely suggest that this will be the
case. In the mouse, infection with H. polygyrus (a nematode
with a life-cycle conﬁned to the gut) modiﬁed the response to a
malaria protein vaccine, resulting in reduced antibody and Th1
responses, increased Th2 and regulatory responses and
impaired protection against malaria challenge.47 Treatment of
the helminth before, but not after, immunisation abrogated
these effects, emphasising the importance of co-infection at the
time of immunisation. Similar effects of H. polygyrus have been
reported for a DNA malaria vaccine, but not for live, irradiated
sporozoites,48 or for live BCG,49 indicating that the impact of a
particular helminth differs by vaccine type: protein, DNA or live
attenuated organisms. Mice infected with Schistosoma species
(which cause systemic infections) show impaired induction of
protective immunity both to malaria50 and to TB challenge
(following BCG),51 indicating that different helminth infections
have different effects. Schistosoma infections also resulted in
Figure 1. Interactions between helminths and the host immune system, and the impact on bystander responses. Red arrows and blue lines denote
positive and suppressive effects, respectively. Helminth migration in the host results in tissue injury, resulting in release of Damage Associated
Molecular Patterns (DAMPs) and alarmins. DAMPs and alarmins are involved in the initial activation of eosinophils, type 2 innate lymphoid cells (ILC2)
and antigen presenting cells (APCs) such as dendritic cells (DCs), which then mediate further inﬂammation in the host. However, some helminth
secretory products can suppress alarmin release and DC maturation, and some helminth enzymes degrade DAMPs. Helminths also interfere with
APC activities, promoting an alternative activation phenotype, which results in production of large amounts of IL-10 and TGFβ. These cytokines
downmodulate eosinophil, ILC2 and DC responses, and promote lymphocyte hyporesponsiveness involving regulatory lymphocytes. Helminth inter-
action with host immunity has spillover effects on responses to bystander antigens. For instance, helminth infections may result in impaired immune
responses to vaccines and communicable diseases, although speciﬁc helminth molecules may actually have enhancing effects. Likewise, there is
evidence for both inverse and positive helminth-allergy associations, although any notable effects on metabolic conditions have been beneﬁcial.
DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid; HMGB1: High Mobility Group Box 1.
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impaired antibody responses to toxoid and protein vaccines—
but a study on hepatitis B immunisation showed a gradual
recovery of the response when the infection was treated after
immunisation.52 The life-cycle of Trichinella spiralis involves an
intestinal phase, followed by encystment in skeletal muscle;
suppression of the IgA response to cholera toxin53 and to hepa-
titis B immunisation54 has been demonstrated during the intes-
tinal, but not the muscle, stages of the life-cycle. While these
experiments demonstrate suppressive effects, intraperitoneal
injection of Ascaris extract concurrently with BCG has been
shown to enhance macrophage activation and suppress BCG
replication55 and a protein from the ﬁlarial worm Onchocerca
volvulus shows promise as an adjuvant for inﬂuenza vaccine.56
Together, studies in mice show that helminth infections have
important potential to supress vaccine responses, but that hel-
minth species, stage of life-cycle, timing of helminth exposure
and treatment, and characteristics of the vaccine may be
important determinants of the outcome and that speciﬁc hel-
minth molecules may actually have enhancing effects. As well,
differences between murine models are likely to result from
genetics of the host and intensity of helminth infection used.
In humans, studies of the impact of helminth co-infection on
vaccine responses are important in their own right, and also
offer an important surrogate for studies on susceptibility to
infections, which are much more difﬁcult to undertake. The
bystander modulatory effects of chronic helminth infections are
of potential direct signiﬁcance in adolescents and adults when
primary or recall immunisation occurs in this age group. For
example, for human papilloma virus immunisation, tetanus and
other boosters, and during outbreaks, such as the recent Yellow
Fever and Ebola epidemics; also when novel vaccines are under-
going initial evaluations in older populations. Observational
studies among children and adults have shown associations
between helminth infection and suppression of antibody and
Th1 responses, particularly during systemic ﬁlarial infections and
schistosomiasis: vaccines affected include BCG, tetanus, typhoid
and a candidate malaria vaccine.57–65 Hepatitis B immunisation
may also be impaired in the context of schistosomiasis66 but
effects may be limited to those with hepatosplenic disease, call-
ing into question the causal mechanisms involved.67 Clinical
trials may help us to test whether helminth induced immuno-
modulation is causal in suppression of vaccine responses and,
so far, these have been conﬁned to effects of geohelminths.
Treatment of geohelminths with albendazole has been shown
to improve the Th1 response to BCG,68,69 and the antibody and
Th1 response to oral cholera vaccine.70,71 No studies have yet
investigated the effects of treating schistosomiasis or ﬁlariases
but, on balance, the data so far suggest that vaccine responses
will improve with the elimination of worms.
However, the majority of vaccines in current use target
pathogens that cause substantial disease and death in early
life. They are administered to the very youngest age groups in
whom chronic helminth infections have yet to establish them-
selves. In these age groups, it is maternal infection status that
is potentially of greatest importance in terms of impacting on a
newborn’s capacity for induction of vaccine-speciﬁc responses.
Evidence that the human fetus could be sensitised in utero to
helminths and mycobacterial antigen72 suggested that prenatal
exposure might inﬂuence infant vaccine responses. Indeed,
initial studies by Malhotra and colleagues showed an associ-
ation between sensitisation to Schistosoma or ﬁlarial antigens in
utero and a Th2 bias to the infant response to BCG immunisa-
tion.73 Malhotra and colleagues also described adverse associa-
tions between prenatal exposure to hookworm and other
helminths and the response to diphtheria toxoid and
Haemophilus inﬂuenzae type B (HiB) immunisation in infancy,74
but this has not been conﬁrmed by results from Uganda where
the only association observed was a possible enhancement of
IgG responses to pertussis toxin, HiB and hepatitis B among
infants of mothers with Strongyloides.25,75,76 A study in Ecuador
also showed no association between exposure to maternal geo-
helminths and infant responses to diphtheria toxoid, tetanus,
pertussis, measles, Rubella or HiB, but enhanced IgA responses
to polio and rotavirus.77 An important consideration is that the
infant outcome may vary depending on the nature and timing
of the exposure to parasite antigens: Malhotra and colleagues
showed that infant DT responses were enhanced if the infant
was sensitised to malaria antigens, but suppressed if the infant
was ‘tolerised’.74 Only one substantive trial has investigated the
effects of treating helminths during pregnancy on infant vaccine
responses: this did not conﬁrm ﬁndings from an earlier pilot78
and gave only weak evidence of an effect of treating maternal
hookworm on the infant response to tetanus or BCG immunisa-
tion.24,25 Further work is needed to understand whether hel-
minth elimination among pregnant women will alter the infant
response to key vaccines.
Given the complex effects of helminths on vaccine responses
it is not surprising that effects on infectious disease susceptibil-
ity are complex too (reviewed elsewhere).79–81 A possible unify-
ing hypothesis, supported by recent evidence from mouse
models,82 is that chronic helminth co-infection has little effect
on the innate response to incident infections (and may even
enhance it) but does impair adaptive responses that control rep-
lication of established infections. For example, in the case of TB,
a recent trial on effects of anthelminthic treatment on bovine
TB among wild buffalo in South Africa’s Kruger National Park
found that regular anthelminthic treatment had no impact on
Mycobacterium bovis infection incidence, but resulted in lower
mortality among M. bovis infected animals.83 Similarly, we found
little evidence that helminth co-infection affects susceptibility to
TB infection in humans,84 but recent results suggest that treat-
ment of helminths may abrogate regulatory T cells-mediated
suppression of Th1 cell frequency and function in helminth-TB
co-infection85 and hints at improved clinical outcome.86
Worms and allergy-related disease
Results from epidemiological studies on the relationship
between helminths and allergy have been inconsistent. As for
vaccine studies, different helminth species interact with the
host’s immune system differently, resulting in different clinical
outcomes. An earlier review and meta-analysis87 found that
hookworm had an inverse association with asthma (summary
odds ratio [OR] 0.50, 95% CI 0.28–0.90), with a ‘dose-response’
by infection intensity, A. lumbricoides showed a positive associ-
ation and T. trichiura showed no relationship. Another meta-
analysis88 showed an inverse association between helminthic
R. E. Sanya et al.
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infections and allergen skin sensitisation (summary OR 0.69,
95% CI 0.6–0.79).
Exposure to helminth infections in-utero and in early child-
hood is negatively associated with allergy risk in childhood.
Our birth cohort in Uganda showed that maternal hookworm
during pregnancy was associated with a reduced incidence of
eczema in childhood (adjusted hazard ration [aHR] 0.71, 95% CI
0.51–0.99), with a dose-response, and that early childhood
infections with T. trichiura and hookworm were associated with
a reduced incidence of childhood eczema.89 Treatment of
maternal helminths during pregnancy increased the incidence
of eczema in childhood.24,90 A study in Brazil also showed that
early childhood infections with T. trichiura and A. lumbricoides
were associated with a lower prevalence of allergen skin reactiv-
ity in later childhood.91 In Gabon, a lower prevalence of skin
reactivity to house dust mite was reported among children
infected with Schistosoma haematobium compared to those
without the infection.92 Most studies have considered helminths
as an independent variable in regression models, but there is
increasing evidence that helminths are effect-modiﬁers of the
relationship between atopy and clinical allergy. We found that
maternal hookworm during pregnancy attenuated the associ-
ation between Dermatophagoides-speciﬁc IgE and eczema in
childhood, as well as the effects of other known risk-factors for
eczema such as mother’s history of eczema and female gen-
der.89 This effect-modiﬁcation has also been reported in studies
in Ecuador.93, 94 A study conducted in Uganda found a positive
association between Dermatophagoides-speciﬁc IgE and hista-
mine release among children without hookworm but not
amongst children with hookworm.95
Despite the inconsistencies outlined, epidemiological studies
have consistently shown a lower prevalence of clinical allergy
(and sometimes atopy) in rural compared to urban areas in low
and middle income countries.96–98 This is consistent with the
observed low prevalence of asthma/allergy among children
raised on farms compared to city dwellers in high income coun-
tries.97 In the high income countries, this farm effect has been
attributed to exposure to diverse microbiome on the farm and
to the consumption of unpasteurised dairy products.98 For low
and middle income countries, the protective effect had been
attributed partly to geohelminths,93 but the possible role of the
microbiome has not yet been extensively explored. Animal stud-
ies have demonstrated interactions between helminths and
microbiota.99 Could the microbiome in rural settings explain
why, in Ugandan island communities, we found a very low
prevalence of clinical allergies, despite positive associations
between helminths and reported wheeze (and atopy)?100
Additionally, there is increasing evidence of attenuation of
the relationship between atopy and allergy among children in
rural compared to urban areas in low and middle income coun-
tries.93,101,102 This has been attributed partly to geohelminths,
but the role of other infections and microbiome deserves
investigation.
Studies on immigrants from rural to urban setting represent
natural experiments. One such study103 found that immigrants
from rural Ethiopia to Israel had a low prevalence of atopy and
allergy, and a negative association between helminth infection
and atopy on arrival, which was quickly reversed after a year of
living in Israel. This was attributed to the treatment of
helminths, a decline in helminths among the untreated, and
exposure to a novel environment.
The helminth-allergy relationship is complicated by the many
inter-related factors at play. To obtain a conclusive stand, we
need to conduct comprehensive studies that take into account
the various helminth-related variables, and the potential inter-
action and confounding with the microbiome, other infections
(such as malaria) and interaction and other environmental
exposures. This will require extensive data collection and
advanced statistical analyses. But the potential beneﬁts are
worth it, for we will be able to understand better how to har-
ness the beneﬁcial effects of worms or the rural environment
for the primary, secondary and tertiary prevention of asthma,
allergies and other chronic inﬂammatory conditions that may
be associated with a life without worms.
Worms and metabolic disease
A recent systematic review showed that individuals with a previ-
ous or current helminth infection were 50% less likely to have
metabolic dysfunction.104
In diet induced obese mice, chronic infection with
Schistosoma mansoni lowered whole body insulin resistance
and glucose intolerance and improved peripheral glucose uptake
and insulin sensitivity. Injection of schistosome antigens induced
a similar effect41 and, in a separate study, reduced atheroscler-
osis in mice.105 Mice infected with H. polygyrus had lower blood
glucose, insulin resistance, fat accumulation than uninfected
mice106 and beneﬁts were sustained even after clearance of the
helminth.107 Nippostrongylus brasiliensis infection was asso-
ciated with decreased weight gain and improved glucose meta-
bolism.108 Similarly, diet induced obese mice infected with
Litomosoides sigmodontis or exposed to its antigen had
improved glucose tolerance.109
In humans, a cross-sectional study in rural China showed
that individuals with a history of schistosomiasis infection exhib-
ited lower fasting blood glucose levels compared to controls
who had never had schistosomiasis.110 A study in India111
reported a lower prevalence of ﬁlarial infections in patients with
type 2 diabetes than in non-diabetic controls. Patients with type
2 diabetes and lymphatic ﬁlariasis had lower concentrations of
pro-inﬂammatory cytokines—IL-6 and GM-CSF—than patients
without lymphatic ﬁlariasis. Among aboriginal adults in
Australia, prior Strongyloides stercoralis infection was associated
with reduced type 2 diabetes risk.112 Infection with STH has also
been associated with decreased insulin resistance and lower
body mass index, abdominal obesity, and lipid levels.113,114
Together, these recent ﬁndings indicate that helminth infec-
tions may convey important beneﬁts for metabolic disease in
humans. If so, understanding the mechanisms with a view to
harnessing this knowledge for prevention and therapy of meta-
bolic disease is important.
Conclusions
Helminths can be damaging, especially when there are intense
infections: therefore, control is good. Some authors have also
argued that MDA is a cost-effective health investment for
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governments115 although, as we have discussed, controlled
trials to date have struggled to conﬁrm a major impact of MDA
on the subtle morbidities and mortality associated with worm
infections in observational studies. As the debate on MDA con-
tinues, we need to note that removal of helminths leaves the
immune system out of balance. We postulate that helminth
elimination will result in a broad array of additional effects, both
beneﬁcial and detrimental to human health. The consequences
may include altered responses to vaccines and to infectious dis-
eases, and increased susceptibility to inﬂammatory conditions such
as allergy-related disease and metabolic disease (Figure 2). Further
work is needed to understand helminth-human interactions and
their mechanisms, so that we can mitigate adverse consequences
in the event that helminth infections in humans are eliminated.
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